FDA Approval Adds Vericiguat (Verquvo) to HF Treatment Options FDA Approval Adds Vericiguat (Verquvo) to HF Treatment Options

The drug with a novel mechanism among HF meds is indicated for an especially high-risk group: patients with LVEF of 45% or less and a history of HF hospitalization or outpatient IV diuretic therapy.FDA Approvals

Source: Medscape Cardiology Headlines - January 20, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news